Literature DB >> 9585256

Characterization of human epidermal growth factor receptor and c-Src interactions in human breast tumor cells.

J S Biscardi1, A P Belsches, S J Parsons.   

Abstract

In C3H/10T1/2 murine fibroblasts, overexpression of both c-Src and the human epidermal growth factor (EGF) receptor 1 (HER1) is required for detection of stable complexes between the two molecules and results in hyperactivation of the receptor and synergistic increases in tumor formation in nude mice, as compared with cells that overexpress only one of the pair. Elevated levels or activities of c-Src and HER1 also occur in a subset of later-stage breast cancers, suggesting that interactions between these two molecules could contribute to a more aggressive clinical course. To determine whether stable complexes between c-Src and HER1 occur in human breast cancers under the same conditions as in murine fibroblasts and whether the appearance of such complexes correlates with enhanced signaling through the EGF receptor and increased tumor growth, human breast tumor cell lines and tumor tissues were analyzed for a number of c-Src/HER1-mediated signaling events and tumorigenicity. In a panel of 14 cell lines, 10 overexpressed c-Src, and of these, five contained elevated levels of HER1 and exhibited an EGF-dependent association between HER1 and c-Src. This association was also present in a HER1/c-Src-overexpressing tumor sample from a breast cancer patient. Further analysis of signaling events revealed that phosphorylation of the HER1 substrate, Shc, and its downstream effector, mitogen-activated protein kinase, was increased in EGF-stimulated MDA-MB-468, MDA-MB-231, and BT-549 cells (which overexpress both c-Src and HER1) as compared with MCF7 and ZR-75-1 cells (which only overexpress c-Src). Furthermore, MDA-MB-468 and MDA-MB-231 cells displayed increased tumorigenicity in nude mice. These results support the hypothesis that c-Src/HER1 interactions contribute to tumor progression in certain late-stage breast tumor cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9585256     DOI: 10.1002/(sici)1098-2744(199804)21:4<261::aid-mc5>3.0.co;2-n

Source DB:  PubMed          Journal:  Mol Carcinog        ISSN: 0899-1987            Impact factor:   4.784


  45 in total

Review 1.  Differential regulation of EphA2 in normal and malignant cells.

Authors:  Jennifer Walker-Daniels; Angela R Hess; Mary J C Hendrix; Michael S Kinch
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

2.  SRC tyrosine kinase inhibitor, m475271, suppresses subcutaneous growth and production of lung metastasis via inhibition of proliferation, invasion, and vascularization of human lung adenocarcinoma cells.

Authors:  Rui Zheng; Seiji Yano; Yuka Matsumori; Emiko Nakataki; Hiroaki Muguruma; Masanori Yoshizumi; Saburo Sone
Journal:  Clin Exp Metastasis       Date:  2005       Impact factor: 5.150

3.  c-Src-mediated epithelial cell migration and invasion regulated by PDZ binding site.

Authors:  Martin Baumgartner; Gerald Radziwill; Mihaela Lorger; Andreas Weiss; Karin Moelling
Journal:  Mol Cell Biol       Date:  2007-11-26       Impact factor: 4.272

4.  Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth.

Authors:  Nagathihalli S Nagaraj; M Kay Washington; Nipun B Merchant
Journal:  Clin Cancer Res       Date:  2011-01-25       Impact factor: 12.531

5.  Multiplexable fluorescence lifetime imaging (FLIM) probes for Abl and Src-family kinases.

Authors:  Sampreeti Jena; Nur P Damayanti; Jackie Tan; Erica D Pratt; Joseph M K Irudayaraj; Laurie L Parker
Journal:  Chem Commun (Camb)       Date:  2020-10-09       Impact factor: 6.222

6.  Mechanism of biological synergy between cellular Src and epidermal growth factor receptor.

Authors:  D A Tice; J S Biscardi; A L Nickles; S J Parsons
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

Review 7.  Pathways to tamoxifen resistance.

Authors:  Rebecca B Riggins; Randy S Schrecengost; Michael S Guerrero; Amy H Bouton
Journal:  Cancer Lett       Date:  2007-05-01       Impact factor: 8.679

8.  Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells.

Authors:  Kelly L Mueller; Lauren A Hunter; Stephen P Ethier; Julie L Boerner
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

9.  The dual kinase complex FAK-Src as a promising therapeutic target in cancer.

Authors:  Victoria Bolós; Joan Manuel Gasent; Sara López-Tarruella; Enrique Grande
Journal:  Onco Targets Ther       Date:  2010-06-24       Impact factor: 4.147

10.  Src kinase phosphorylates RUNX3 at tyrosine residues and localizes the protein in the cytoplasm.

Authors:  Yun-Mi Goh; Senthilkumar Cinghu; Eileen Tan Hwee Hong; You-Soub Lee; Jang-Hyun Kim; Ju-Won Jang; Ying-Hui Li; Xin-Zi Chi; Kyeong-Sook Lee; Heejun Wee; Yoshiaki Ito; Byung-Chul Oh; Suk-Chul Bae
Journal:  J Biol Chem       Date:  2010-01-25       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.